Inhalable formulations to treat non-small cell lung cancer (NSCLC): Recent therapies and developments

C Gupta, A Jaipuria, N Gupta - Pharmaceutics, 2022 - mdpi.com
Cancer has been the leading cause of mortalities, with lung cancer contributing 18% to
overall deaths. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung
cancers. The primary form of therapy used to treat lung cancer still includes oral and
systemic administration of drugs, radiotherapy, or chemotherapy. Some patients have to go
through a regime of combination therapy. Despite being the only available form of therapy,
their use is limited due to the adverse effects, toxicity, and development of resistance over …

[PDF][PDF] Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments. Pharmaceutics 2023, 15, 139

C Gupta, A Jaipuria, N Gupta - 2022 - academia.edu
Cancer has been the leading cause of mortalities, with lung cancer contributing 18% to
overall deaths. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung
cancers. The primary form of therapy used to treat lung cancer still includes oral and
systemic administration of drugs, radiotherapy, or chemotherapy. Some patients have to go
through a regime of combination therapy. Despite being the only available form of therapy,
their use is limited due to the adverse effects, toxicity, and development of resistance over …
以上显示的是最相近的搜索结果。 查看全部搜索结果